Hema Diagnostic Systems Announces the Sepsis Development Team

MIRAMAR, FL / ACCESSWIRE / January 30, 2017 / Hema Diagnostic Systems, located in Miramar, Florida, USA, a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTC PINK: GNBT), is proud to announce that Harold G. Haines, Ph.D., will expand his participation at Hema Diagnostic Systems to include project management of a new and novel multiplex assay designed for use with Sepsis. This new device has been issued the preliminary designation of RAPID 1-2-3® HEMA® SEPSIS. Dr. Haines will lead a coordinated effort involving both Hema Diagnostic Systems and Generex Biotechnology and will undertake the new responsibilities of Chief Medical Officer for Hema Diagnostic Systems while retaining his current responsibilities as Director of Clinical Affairs, a position held since 2002.

Dr. Haines has 45 plus years of executive managerial and consulting experience in the healthcare industry, with a broad background in pharmaceuticals, diagnostics, medical devices, and therapeutics and is a former tenured Professor of Pathology (with appointments in Microbiology, Immunology, Dermatology, and Obstetrics and Gynecology) at the University of Miami School of Medicine, Miami, Florida. He also established and served as Director of the Clinical Virology Laboratory at Jackson Memorial Hospital, the second largest hospital in the United States. Dr. Haines was founder and Director of the Virology Reference Laboratory at the University of Miami – School of Medicine. Both of these laboratories were among the first laboratories for the diagnosis of viral diseases in the Southeastern United States. He has founded and operated two commercial immunology and infectious disease laboratories.

According to Dr. Haines, “Sepsis is a rapidly developing inflammatory syndrome and one of the major causes of serious disability and death in hospital settings in the United States and globally. Because it can develop and intensify extremely fast in a patient, it is critical that a very rapid and accurate diagnosis be made.” Dr. Haines further stated,”Hema Diagnostic Systems is developing a multiplex assay for the detection and quantitative determination of several distinct biomarkers for the diagnosis of this devastating syndrome. The results of this assay, which can be conducted either at bedside or in a central laboratory, will be available in 10-15 minutes. This multiplex assay aims to help determine the status and origin of sepsis, which is a major cause of death in hospitals, with very high predictability. This, in turn, will give the physician essential information to take the necessary treatment steps in a manner which is much more efficient and rapid than currently available tests.”

Dr. Haines will be working with Dr. Jason Terrell, Chief Medical and Scientific Officer of Generex Biotechnology, in the development of the new Rapid 1-2-3 Hema Sepsis diagnostic. Dr. Terrell stated,”We are very fortunate to have Dr. Haines accept this position. Dr. Haines is among the most experienced and innovative diagnostic test developers in the industry. I look forward to working alongside him in development of the sepsis diagnostic and all future endeavors.”

Lawrence Salvo, President and CEO of Hema Diagnostic Systems, confirmed the commitment of HDS to the Sepsis Project: “Sepsis will be a major step forward for Hema Diagnostic Systems and will bring our technology in to new markets that will serve as a base for further product development and expansion. Dr. Haines and Dr. Terrell constitute a powerful team and we look forward to their success. HDS is committed to this effort which is greatly needed, not only here in the United States, but on a worldwide basis.”

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company’s products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company’s dependence on key personnel, third party sales, and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results.

For further information, please contact Hema Diagnostic Systems at:

info@rapid123.com or at +1-954-919-5123

SOURCE: Hema Diagnostic Systems

ReleaseID: 453718